Systemic lupus erythematosus and "lupus dyslipoproteinemia"

Autoimmunity Reviews

Volumn 7, Issue 3, 2008, Pages 246-250

  de Carvalho, Jozélio Freire ^a   Bonfá, Eloísa ^a   Borba, Eduardo Ferreira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Dyslipidemia; Dyslipoproteinemia; Lipoprotein; Systemic lupus erythematosus

Indexed keywords

APOLIPOPROTEIN A1; AUTOANTIBODY; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CHYLOMICRON; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DYSLIPOPROTEINEMIA; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIPOPROTEIN METABOLISM; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOANTIBODIES; DYSLIPIDEMIAS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 37749038565     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2007.11.016     Document Type: Review

References (40)

1. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112 (2005) 3337-3347
2. Petri M., Perez-Gutthann S., Spence D., and Hochberg M.C. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93 (1992) 513-519
3. Svenungsson E., Jensen-Urstad K., Heimburger M., Silveira A., Hamsten A., Hamsten U., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104 (2001) 1887-1893
4. Hamsten A.B., Godfrey T., Rowley K.G., Karschimkus C.S., Dragicevic G., Romas E., et al. Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J 36 (2006) 237-243
5. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
6. Borba E.F., Carvalho J.F., and Bonfá E. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol 13 (2006) 203-208
7. Glueck C.J., Levy R.I., Glueck H.I., Gralnick H.R., Greten H., and Fredrickson D.S. Acquired type I hyperlipoproteinemia with systemic lupus erythematosus, dysglobulinemia and heparin resistance. Am J Med 47 (1969) 318-324
8. Ilowite N.T., Samuel P., Ginzler E., and Jacobson M.S. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31 (1988) 859-863
9. Borba E.F., and Borba E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6 (1997) 533-539
10. Jacobs Jr. D.R., Jacobs I.L., Bangdiwala S.I., Criqui M.H., and Tyroler H.A. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the Follow-up Study of the Lipid Research Clinics' Prevalence Study. Am J Epidemiol 131 (1990) 32-47
11. Kawanishi K., Ueda H., Nagase M., and Ofuji T. Decreased plasma postheparin lipolytic activity in systemic lupus erythematosus. Acta Med Okayama 31 (1977) 319-324
12. Deckelbaum R.J., Granot E., Oschry Y., Rose L., and Eisenberg S. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis 4 (1984) 225-231
13. Borba E.F., Bonfa E., Vinagre C.G., Ramires J.Á., and Maranhão R.C. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43 (2000) 1033-1040
14. de Carvalho J.F., Borba E.F., Viana V.S., Bueno C., Leon E.P., and Bonfá E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?. Arthritis Rheum 50 (2004) 3610-3615
15. Chait A., Brazg R.L., Tribble D.L., and Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94 (1993) 350-356
16. Frostegard J., Svenungsson E., Wu R., Gunnarsson I., Lundberg I.E., Klareskog L., et al. Lipid peroxidation is enhanced in patients with systemic lupuserythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52 (2005) 192-200
17. Vaarala O., Alfthan G., Jauhiainen M., Leirisalo-Repo M., Aho K., and Palosuo T. Cross-reaction between antibodies to oxidized low density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341 (1993) 923-925
18. Dinu A.R., Merrill J.T., Shen C., Antonov I.V., Myones B.L., and Lahita R.G. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7 (1998) 355-360
19. McMahon M., Grossman J., FitzGerald J., et al. Pro-inflammatory HDL as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54 (2006) 2541-2549
20. Lahita R.G., Rivkin E., Cavanagh I., and Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36 (1993) 1566-1574
21. Kobayashi K., Matsuura E., Liu Q., Furukawa J., Kaihara K., Inagaki J., et al. A specific ligand for beta-2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 42 (2001) 697-709
22. Lopez L.R., Salazar-Paramo M., Palafox-Sanchez C., Hurley B.L., Matsuura E., and Garcia-De La Torre I. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 15 (2006) 80-86
23. Asanuma Y., Chung C.P., Oeser A., Shintani A., Stanley E., Raggi P., et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 33 (2006) 539-545
24. Enholm C., Aho K., Huttunen J.K., Kostiainen E., Mattila K., Pakkarainen J., et al. Effect of interferon on plasma lipoproteins and on the activity of postheparin lipases. Arteriosclerosis 2 (1982) 69-73
25. Svenungsson E., Gunnarsson I., Fei G.Z., Lundberg I.E., Klareskog L., and Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48 (2003) 2533-2540
26. Frostegard M.K., Binder C.J., Torzewski M., and Torzewski J.L. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 99 (2002) 13043-13048
27. Anaya J.M., et al. Familial clustering of autoimmune diseases in patients with type 1 diabetes mellitus. J Autoimmun 26 (2006) 208-214
28. Bjornvold M., et al. FOXP3 polymorphisms in type 1 diabetes and coeliac disease. J Autoimmun 27 (2006) 140-144
29. Brandt D., and Gershwin M.E. Common variable immune deficiency and autoimmunity. Autoimmun Rev 5 (2006) 465-470
30. Bucciarelli S., et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev 6 (2006) 72-75
31. Deshmukh U.S., Bagavant H., and Fu S.M. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun Rev 5 (2006) 414-418
32. Duan B., and Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 5 (2006) 403-408
33. Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev 6 (2006) 98-103
34. Gupta B., et al. Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance. J Autoimmun 27 (2006) 125-133
35. Khan N.A., et al. N-3 fatty acids modulate Th1 and Th2 dichotomy in diabetic pregnancy and macrosomia. J Autoimmun 26 (2006) 268-277
36. Lapierre P., et al. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J Autoimmun 26 (2006) 82-89
37. Ola T.O., et al. Importin beta: a novel autoantigen in human autoimmunity identified by screening random peptide libraries on phage. J Autoimmun 26 (2006) 197-207
38. Rieger R., et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun 27 (2006) 7-16
39. Strous R.D., and Shoenfeld Y. To smell the immune system: olfaction, autoimmunity and brain involvement. Autoimmun Rev 6 (2006) 54-60
40. Szekanecz E., et al. Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev 6 (2006) 42-47